Soluble CTLA-4 - A confounding factor in CTLA-4 based checkpoint immunotherapy in cancer

Parviz Azimnasab-Sorkhabi; Maryam Soltani-Asl; Musab Bouhajra; Ephraim A Ansa-Addo; Jose Roberto Kfoury Junior

doi:10.1016/j.imlet.2024.106965

Soluble CTLA-4 - A confounding factor in CTLA-4 based checkpoint immunotherapy in cancer

Immunol Lett. 2024 Dec 10:106965. doi: 10.1016/j.imlet.2024.106965. Online ahead of print.

Authors

Parviz Azimnasab-Sorkhabi¹, Maryam Soltani-Asl², Musab Bouhajra³, Ephraim A Ansa-Addo³, Jose Roberto Kfoury Junior⁴

Affiliations

¹ Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil; Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. Electronic address: Sorkhabi.parviz@gmail.com.
² Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil; Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
³ Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
⁴ Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil.

PMID: 39667581
DOI: 10.1016/j.imlet.2024.106965

Abstract

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a receptor that inhibits the activity of T cells. The CTLA-4 gene consists of four different exons that enable four different isoforms of CTLA-4 to be generated through alternative splicing. Although sCTLA-4 might impede the therapeutic effect of anti-CTLA-4 treatments, the role of sCTLA-4 in the tumor microenvironment (TME) is not well understood. Here, we provide novel perspectives on the inhibitory characteristics of sCTLA-4 in TME.

Keywords: CTLA-4; CTLA-4 isoforms; Immunotherapy(,) Cancer; sCTLA-4.

Publication types

Review